Yissum - Research Development Company of the Hebrew University

Novel Biomarker for the Detection of Preeclampsia

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

New Molecular species of alternatively VEGF receptor 1(sFlt-14) for diagnosis and prognosis of preeclampsia and other diseases

Project ID : 6-2010-2505

Yissum - Research Development Company of the Hebrew University

Description of the technology

Project Summary

A human-specific splicing variant of vascular endothelial growth factor (VEGF) receptor 1 (Flt1) was discovered, producing a soluble receptor (designated sFlt1-14) that is qualitatively different from the previously described soluble receptor (sFlt1) and functioning as a potent VEGF inhibitor. sFlt1-14 is generated in a cell type-specific fashion, primarily in nonendothelial cells.

Increased production of soluble VEGF receptors during pregnancy is entirely attributable to induced expression of placental sFlt1-14 starting by the end of the first trimester.

sFlt1-14 is the predominant VEGF-inhibiting protein produced by the preeclampsia placenta, accumulates in the circulation, and hence is capable of neutralizing VEGF in distant organs affected in preeclampsia. We have developed two antibodies to the human-specific isoform of the gene responsible for preeclampsia that was shown to be extremely valuable for diagnosis and prognosis of preeclampsia. The technology was validated in two cohorts of early and late onset preeclampsia patient samples were used to measure and evaluate the clinical performance of total sFLT, sFLT1-13 and sFLT1-14.

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Eli Keshet
HUJI, School of Medicine - IMRIC
Developmental Biology and Cancer Research

Related keywords

  • Clean Industrial Technologies
  • Other (uncategorised)
  • Life Science & Biotechnology
  • diagnostics

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.